What we are studying
Participants are being asked to take part in this study because they have been diagnosed with a cancer that has spread and cannot be surgically removed. A phase I clinical trial to determine the toxicities of a single intravenous administration of APN401 established feasibility and safety. This clinical trial will examine multiple infusions and also provide an initial estimate of immunologic activity. The overall goal is to determine if there is sufficient evidence of safety and immunologic activity to proceed to phase II clinical trials, alone or in combination with other antitumor agents.
Parking will be validated for study-related visits